Pharsight

Klisyri is owned by Almirall.

Klisyri contains Tirbanibulin.

Klisyri has a total of 8 drug patents out of which 0 drug patents have expired.

Klisyri was authorised for market use on 14 December, 2020.

Klisyri is available in ointment;topical dosage forms.

Klisyri can be used as topical treatment of actinic keratosis of the face or scalp.

Drug patent challenges can be filed against Klisyri from December, 2024.

The generics of Klisyri are possible to be released after 07 September, 2038.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236799	ALMIRALL	Biaryl compositions and methods for modulating a kinase cascade	Dec, 2025 (2 years from now)
US8980890	ALMIRALL	Compositions and methods of treating cell proliferation disorders	Dec, 2025 (2 years from now)
US7300931	ALMIRALL	Compositions for treating cell proliferation disorders	Feb, 2026 (3 years from now)
US7851470	ALMIRALL	Composition and methods for modulating a kinase cascade	Feb, 2029 (6 years from now)
US10669236	ALMIRALL	Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide	Sep, 2038 (15 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001	ALMIRALL	Compositions for modulating a kinase cascade and methods of use thereof	Dec, 2027 (4 years from now)
US10617693	ALMIRALL	Methods of treating and/or preventing actinic keratosis	Mar, 2038 (15 years from now)
US11497750	ALMIRALL	Methods of treating and/or preventing actinic keratosis	Mar, 2038 (15 years from now)